par Gebhart, Géraldine ;Gamez, Cristina;Holmes, Eileen;Robles Barba, Javier;Garcia, Camilo ;Cortés, Montserrat;de Azambuja, Evandro ;Fauria, Karine;van Dooren, Veerle;Aktan, Gursel;Coccia-Portugal, Maria;Kim, Sung-Bae;Vuylsteke, Peter;Cure, Hervé;Eidtmann, Holger;Baselga, José;Piccart-Gebhart, Martine ;Flamen, Patrick ;Di Cosimo, Serena
Référence The Journal of nuclear medicine, 54, 11, page (1862-1868)
Publication Publié, 2013-11
Référence The Journal of nuclear medicine, 54, 11, page (1862-1868)
Publication Publié, 2013-11
Article révisé par les pairs
Résumé : | Molecular imaging receives increased attention for selecting patients who will benefit from targeted anticancer therapies. Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) enrolled 455 women with invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer and compared rates of pathologic complete response (pCR) to neoadjuvant lapatinib, trastuzumab, and their combination. Each anti-HER2 therapy was given alone for 6 wk, followed by 12 wk of the same therapy plus weekly paclitaxel. The early metabolic effects of the anti-HER2 therapies on the primary tumors and their predictive values for pCR were assessed in a subset of patients. |